Dr. Benjamin: By way of background, Rodman & Renshaw is a full-service investment bank with a focus on small to mid-cap biotechnology and technology companies. We are committed to the long-term development of emerging companies through value-added equity research, institutional sales and trading, strategic advice, and capital raising. Our equity research, sales and trading efforts cater only to institutional clients looking to invest in undervalued, under-covered companies with outstanding technologies. Currently, the biotechnology team consists of seven PhDs of which four are senior analysts including myself, Elemer Piros, David Wood and Navdeep Jaikaria. Combined, we cover a wide range of therapeutic categories including oncology, cardiology, infectious disease, inflammation and autoimmune diseases. Companies currently under coverage by the biotech team at Rodman include Aksys (AKSY), Alteon (ALT), Ariad Pharmaceutical (ARIA), Applied Molecular Evolution (AMEV), AVI BioPharma (AVII), Cepheid (CPHD), CollaGenex Pharmaceuticals (CGPI), Cypress Bioscience (CYPB), Dyax (DYAX), Encysive Pharmaceuticals (ENCY), Genelabs Technologies (GNLB), Genta (GNTA), Geron (GERN), InKine Pharmaceuticals (INKP), Isis Pharmaceuticals (ISIS), Repligen (RGEN), Rita Medical Systems (RITA), SuperGen (SUPG), Tanox (TNOX) and United Therapeutics (UTHR). As part of Rodman and Renshaw's continued growth and development, the company acquired all the rights to the Annual Techvest Healthcare Conference. The conference, to be held in Boston from October 21-23, 2003, will host over 150 public and private companies, as well as a large number of institutional and venture capital investors.
TWST: What are you going to do with it?
Dr. Benjamin: In addition to panel discussions with independent experts
helping to sift through complex issues surrounding biotechnology and
thought provoking and vibrant keynote speakers, we will showcase
upcoming growth companies that we believe comprise the next generation
of biotechnology companies. We already have over 150 public and private
companies presenting to a large audience of institutional investors.
Tickers included in this excerpt: AKSY, ALT, AMEV, ARIA, ASCO, AVII, AZN, BGEN, BMRN, CGPI, CPHD, CYPB, DNA, DYAX, ENCY, GENZ, GERN, GNLB, GNTA, INKP, ISIS, MEDI, MLNM, NVS, RGEN, RITA, SUPG, TNOX, UTHR
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.